Companies › Candid Therapeutics
3 active drug programs in 6 registered trials: 6 Phase 1; Immunology, Neurology, Ophthalmology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CND261 | – | Phase 1 | Rheumatoid Arthritis | Jun 2027 |
| Cizutamig (CND106) IGF-1 receptor antagonist | IGF1R | Phase 1 | Generalized Myasthenia Gravis; Systemic Lupus Erythematosus (SLE); Thyroid Eye Disease, TED; Rheumatoid Arthritis (RA) | Dec 2027 |
| CND319 | – | Phase 1 | Healthy Participants Study | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07052032 | CND261 | Phase 1 | Rheumatoid Arthritis | Immunology | Jun 2027 |
| NCT06946199 | Cizutamig (CND106) | Phase 1 | Rheumatoid Arthritis (RA) | Immunology | Jun 2027 |
| NCT07215650 | Cizutamig (CND106) | Phase 1 | Generalized Myasthenia Gravis | Neurology | Dec 2027 |
| NCT07215663 | Cizutamig (CND106) | Phase 1 | Systemic Lupus Erythematosus (SLE) | Immunology | Dec 2027 |
| NCT07712939 | CND319 | Phase 1 | Healthy Participants Study | Immunology | Mar 2028 |
| NCT07597200 | Cizutamig (CND106) | Phase 1 | Thyroid Eye Disease, TED | Ophthalmology | May 2028 |
Innovent Biologics (Suzhou) OHB Neonatology Amgen Viridian Therapeutics Minghui Pharmaceutical (Hangzhou) Sling Therapeutics Zai Lab (Shanghai)
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.